Pre-Revenue Company Valuation
Which valuation methods would be appropriate in valuing a private, pre-revenue medical device company whose product is pending FDA approval?
Trending Content
| +84 | GF doesn’t care about her looks | 49 | 16h | |
| +55 | Affair with my Associate… In Desperate Need for Advice | 23 | 8h | |
| +41 | How to sound more eloquent? | 16 | 5h | |
| +39 | Insurance as High Finance? | 10 | 2d | |
| +38 | 400k/year in HVAC sales? | 26 | 1d | |
| +33 | Would you rather live alone in an outer borough or with roommates in Manhattan? | 23 | 2d | |
| +27 | WSO Ranking On Resume??? | 6 | 8h | |
| +27 | Why do people listen to Jim Cramer Investing Advice? | 10 | 10h | |
| +26 | Is my boss gaslighting me? | 3 | 8h | |
| +25 | Carnivore Diet | 9 | 10h |
Career Resources
The cheap answer is: get direction from someone more senior than you and do whatever they say.
But if you are looking for more of an interview answer, you would probably do what you do for most biotech companies, which is project out expected revenue from their device given there is only X percentage of approval at each phase. Because this is a medical device and not a drug it might work a little differently but would be similar. If there are decent comps look at those too
I used to work at a pharma/biotech focuses consulting firm. I'd look at this way: what's the total addressable population (people with disease state), how well is it served (do current therapies work ok? Are they cheap? Tolerable?) and what share am I going to garner (first line v second line label, disease severity). Once you've figured out how many people will take the medication then figure out analogs (price comparators for similar indications or perceived level of unmet need) figure in your discounting and rebating then project uptake (quick in oncology potentially very slow in dermatology). Price increases project 3-5% per annum. Don't forget to weight the probability of approval.
Does anyone have a pre-revenue biotech model they could share? (Originally Posted: 12/27/2017)
Hi --
Currently in the process of building a valuation for a pre-revenue biotech company with a clinical stage pipeline (mostly Phase I/II). This is just a learning exercise for me, and I'd love to reference my work alongside someone else's. I understand how to build the valuation from a fundamental standpoint -- weighting the FCFs by the chance of approval, etc. However, I would love a shell to work from. Would anybody be willing to provide me with a bare bones example? It'd be much appreciated. Thank you.
Best, Cabbage
Blanditiis occaecati occaecati fugit pariatur aliquid. Cum earum sunt deserunt dolor tenetur magni iste. Earum libero aut voluptatem vero quo. Ipsam doloribus aut omnis. Magni cumque laborum deserunt ut et.
Rerum sed et quam ex voluptate. Quo iusto aut deleniti perspiciatis. Cum impedit officia suscipit tempora. Voluptas dignissimos qui quis et sit fugiat quod a.
Sunt quia maxime quasi ab non cum qui cum. Aut et aperiam optio qui doloribus recusandae aut. Quis aliquam assumenda error dolor et aspernatur. Assumenda sit unde at alias.
Ullam eveniet laudantium iusto nemo et a consectetur provident. Et voluptatem ab dignissimos tenetur non quasi recusandae. Ex rem possimus accusantium cum nisi doloribus.
See All Comments - 100% Free
WSO depends on everyone being able to pitch in when they know something. Unlock with your email and get bonus: 6 financial modeling lessons free ($199 value)
or Unlock with your social account...